Winter Storm Disrupts Northeast Travel as Snow and Ice Blanket New York, New Jersey 
Star Entertainment Leadership Shake-Up Deepens as CFO and COO Exit Amid Ongoing Restructuring 
China’s Iron Ore Buyer Pressures Mining Giants as New Supply Shifts Market Power 
Sanofi to Acquire Dynavax in $2.2 Billion Deal to Strengthen Vaccines Portfolio 
Brazilian Oil Workers’ Strike Continues as Key Petrobras Union Rejects Proposal 
China’s LandSpace Takes Aim at SpaceX With Reusable Rocket Ambitions 
Trump Administration Probes Corporate DEI Programs, Raising Questions for Google Stock 
Nvidia to Acquire Groq in $20 Billion Deal to Boost AI Chip Dominance 
Hanwha Signals Readiness to Build Nuclear-Powered Submarines at Philly Shipyard for U.S. Navy 
TSMC Honors Japanese Chip Equipment Makers With 2025 Supplier Awards 
Boeing Wins $2.04B U.S. Air Force Contract for B-52 Engine Replacement Program 
GLP-1 Weight Loss Pills Set to Reshape Food and Fast-Food Industry in 2025 
DOJ Reaches Settlement With Blackstone’s LivCor Over Alleged Rent Price-Fixing 
Nvidia and Groq Strike Strategic AI Inference Licensing Deal 
BP Nears $10 Billion Castrol Stake Sale to Stonepeak 
Leapmotor Targets 4 Million Annual EV Sales as Global Expansion Accelerates 
Nike Stock Jumps After Apple CEO Tim Cook Buys $2.9M Worth of Shares 
SAN FRANCISCO, Nov. 14, 2016 -- iRhythm Technologies, Inc. (NASDAQ:IRTC), a leading digital health care solutions company focused on the advancement of cardiac care, today announced that it will release financial results for the third quarter 2016 after the close of trading on Monday, December 5, 2016. The company’s management team will host a corresponding conference call beginning at 1:30 p.m. PT / 4:30 p.m. ET.
Investors interested in listening to the conference call may do so by dialing (844) 348-0016 for domestic callers or (213) 358-0876 for international callers, or access the webcast on the “Investor Relations” section of the company’s website at: www.irhythmtech.com.
About iRhythm Technologies, Inc.
iRhythm is a commercial-stage digital health care company redefining the way cardiac arrhythmias are clinically diagnosed. The company combines wearable biosensor devices worn for up to 14 days and cloud-based data analytics with powerful proprietary algorithms that distill data from millions of heartbeats into clinically actionable information. The company believes improvements in arrhythmia detection and characterization have the potential to change clinical management of patients. The company’s platform, the Zio Service, has been provided to over 500,000 patients, accumulating more than 125 million hours of curated heartbeat data within iRhythm’s data repository.
Investor Relations Contact: Lynn Pieper Lewis or Leigh Salvo (415) 937-5404 [email protected] Media Contact Aaron Murphy (415) 229-3331 [email protected]
